Small cell lung cancer, accounting for approximately 14% of lung cancer cases, remains one of the most aggressive malignancies. Despite its lower incidence compared to non-small cell lung cancer, its early metastasis and rapid progression make small cell lung cancer a major public health concern due to poor survival outcomes. Five-year survival rates remain below 7% for extensive-stage disease, highlighting the urgent need for improved diagnostic and therapeutic strategies. Although epidemiologically small cell lung cancer is considered less hazardous than in previous decades, it continues to pose a substantial global public health burden. Changes in epidemiology include a narrowing of the historical male predominance, regional variations, and higher age-standardized incidence rates in Eastern Asia, Micronesia, Polynesia, Northern Europe, and North America. Although long-term survival remains limited, significant improvements with modern treatment options have been reported. Platinum-based chemotherapy combined with etoposide remains the first-line standard for both limited-stage and extensive-stage small cell lung cancer. Thoracic radiotherapy, prophylactic cranial irradiation to reduce the risk of brain metastases, and surgery for highly selected early-stage patients are among current treatment modalities, alongside second-line therapies such as topotecan. In parallel, novel therapeutic approaches primarily immunotherapies and patient-specific targeted therapies are showing substantial promise. The use of immune checkpoint inhibitors in combination with chemotherapy has been shown to improve survival in extensive-stage small cell lung cancer. Furthermore, integration of bispecific T-cell engagers targeting delta-like canonical Notch ligand 3, antibody-drug conjugates, poly-adenosine diphosphate ribose polymerase inhibitors, and epigenetic modulators with existing treatment strategies represents a promising direction for future therapy. Despite challenges including small trial sizes, resistance mechanisms, and treatment-related toxicity, these approaches may become more widely used in clinical practice. Overall, small cell lung cancer remains a serious clinical challenge that requires continued development of novel treatment strategies. These emerging approaches hold significant potential for providing more patient-specific therapeutic options. Ongoing and future clinical trials will be critical for establishing effective treatment algorithms and improving long-term outcomes in patients with this aggressive cancer. In this context, immunotherapy has emerged as a cornerstone of modern small cell lung cancer management, particularly in extensive-stage disease. Understanding the biological basis of immunotherapy responsiveness and resistance is therefore essential for optimizing current and future treatment strategies.
Building similarity graph...
Analyzing shared references across papers
Loading...
Günel et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69a528b3f1e85e5c73bf03ff — DOI: https://doi.org/10.4274/tmsj.galenos.2026.2025-9-4
Kerem Mintaze Günel
Nehir Özyedek
Ahmet Onur Oğuz
TURKISH MEDICAL STUDENT JOURNAL
SHILAP Revista de lepidopterología
Building similarity graph...
Analyzing shared references across papers
Loading...